Moderna — Jan 12, 2026 release

Morgan Healthcare Conference Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call Improves 2025 expected GAAP operating expenses by $200 million since 3Q25 Earnings Call Increases 2025 projected year-end cash balance to approximately $8.1 billion (unaudited) Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026 Anticipates potential first approvals of flu and flu/COVID combination products in 2026 Expects pivotal trial data readouts in oncology, rare disease and infectious disease in 2026 CAMBRIDGE, MA / ACCESSWIRE / January 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2026 with a focus on growing sales, launching new infectious disease products and delivering pivotal readouts across oncology, rare disease and infectious disease portfolios. “In 2025, we strengthened our commercial execution, successfully launched our third product, and continued to advance our mRNA pipeline. At the same time, we reduced our annual operating expenses by approximately $2 billion, significantly exceeding the financial cost reduction commitments we set at the start of the year,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We remain focused on our strategy to build a large seasonal vaccine franchise for at-risk populations, creating a strong cash engine to fund our next phase of innovation in oncology and